Rate My Professor Thozhukat Sathyapalan

His research specializes in modulating cardiovascular risk through pharmacological and lifestyle interventions in insulin-resistant conditions, including obesity, polycystic ovary syndrome, and type 2 diabetes mellitus, with emphasis on traditional and novel risk factors such as endocrine disruptors. He leads the Academic Endocrinology, Diabetes and Metabolism Group at Hull York Medical School and the Diabetes, Metabolic and Endocrinology Research Delivery Network for Yorkshire and Humber since 2014. Key publications include co-authorship on high-impact papers such as 'Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial' (The Lancet, 2019), '3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial' (The Lancet, 2017), 'Molecular mechanisms linking oxidative stress and diabetes mellitus' (Oxidative Medicine and Cellular Longevity, 2020), 'Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial' (The Lancet, 2019), and 'Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial' (The Lancet Diabetes & Endocrinology, 2017). With over 21,000 citations and 588 publications, his work has significant influence in endocrinology. He has supervised 16 postgraduate students to completion since 2010 and currently supervises several PhD and MD students. Sathyapalan organizes the RCP-accredited Continuing Medical Education programme for endocrine trainees and consultants, delivers plenary lectures and teaching clinics, and serves as an examiner and supervisor for medical students and trainees. He chaired the Hull York Medical School Ethics Committee from 2016 to 2024.